ArticleWorld journal of clinical pediatrics2026
Sirolimus for the treatment of vascular tumors and malformations in children: A 10-year single-institution retrospective study.
Article in World journal of clinical pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVascular anomalies, including vascular tumors and vascular malformations, are common pediatric conditions that may cause significant morbidity. Although standard treatments are effective in many cases, a subset of patients experiences inadequate responses or has unresectable disease, necessitating alternative therapeutic strategies. Sirolimus has emerged as a targeted treatment option for selected vascular anomalies.
aimTo evaluate treatment outcomes and the safety of sirolimus in children with vascular anomalies.
methodsWe conducted a retrospective review of medical records of pediatric patients with vascular anomalies who received sirolimus at Chiang Mai University Hospital between 2016 and 2025. Clinical characteristics, treatment regimens, therapeutic responses, and adverse events were analyzed.
resultsEleven children were included in the study. Five patients had vascular tumors, including two kaposiform hemangioendotheliomas, one composite hemangioendothelioma, and two hemangiomas, while six patients had vascular malformations. Sirolimus was administered as salvage therapy in nine patients. After sirolimus treatment, 10 patients (90.9%) achieved partial response, and one patient had stable disease. At a median follow-up of 30 months, all patients were alive with disease. Sirolimus-related adverse events occurred in four patients, with proteinuria being the most common. Other events included hypokalemia, elevated serum creatinine, and hypercholesterolemia. No serious infections were observed.
conclusionSirolimus demonstrated a high response rate and an acceptable safety profile in children with vascular anomalies. These findings support the use of sirolimus as an effective treatment option for refractory or unresectable cases, including complex entities such as composite hemangioendothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.